Oncolytic adenovirus and doxorubicin‐based chemotherapy results in synergistic antitumor activity against soft‐tissue sarcoma

@article{Siurala2015OncolyticAA,
  title={Oncolytic adenovirus and doxorubicin‐based chemotherapy results in synergistic antitumor activity against soft‐tissue sarcoma},
  author={M. Siurala and Simona Bramante and L. Vassilev and M. Hirvinen and S. Parviainen and S. T{\"a}htinen and K. Guse and V. Cerullo and A. Kanerva and A. Kipar and M. V{\"a}h{\"a}-Koskela and Akseli Hemminki},
  journal={International Journal of Cancer},
  year={2015},
  volume={136}
}
  • M. Siurala, Simona Bramante, +9 authors Akseli Hemminki
  • Published 2015
  • Biology, Medicine
  • International Journal of Cancer
  • Despite originating from several different tissues, soft‐tissue sarcomas (STS) are often grouped together as they share mesenchymal origin and treatment guidelines. Also, with some exceptions, a common denominator is that when the tumor cannot be cured with surgery, the efficacy of current therapies is poor and new treatment modalities are thus needed. We have studied the combination of a capsid‐modified oncolytic adenovirus CGTG‐102 (Ad5/3‐D24‐GMCSF) with doxorubicin, with or without… CONTINUE READING
    36 Citations
    Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances
    • 49
    • PDF
    Oncolytic adenovirus: A tool for cancer therapy in combination with other therapeutic approaches
    • 12
    Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors
    • PDF

    References

    SHOWING 1-10 OF 47 REFERENCES
    Serotype chimeric oncolytic adenovirus coding for GM‐CSF for treatment of sarcoma in rodents and humans
    • 32
    • PDF
    Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF.
    • 207
    Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel.
    • 179
    • PDF
    Combination of gemcitabine and Ad5/3-Δ24, a tropism modified conditionally replicating adenovirus, for the treatment of ovarian cancer
    • 92
    • PDF